Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - 1st line (L1), anti-CTLA-4 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results A3671009, 2013 0.88 [0.75; 1.04]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs I ; all population), 2015 0.55 [0.42; 0.72]
CheckMate 069 (all population), 2015 0.74 [0.43; 1.27]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1.44 [0.46; 4.49]
0.72 [0.56 ; 0.92 ] A3671009, 2013, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 5 66% 2,090 low not evaluable deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.52 [0.42; 0.64]
0.58 [0.48 ; 0.69 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015 2 43% 1,260 low not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.35; 0.51]
CheckMate 069 (all population), 2015 0.36 [0.23; 0.57]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.47 [0.10; 2.27]
0.46 [0.39 ; 0.54 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 4 28% 1,435 low not evaluable progression or deaths (PFS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.31; 0.57]
CheckMate 069 (all population), 2015 0.38 [0.23; 0.63]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.38 [0.15; 0.98]
CheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69]
0.46 [0.39 ; 0.55 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015 5 0% 1,544 low not evaluable objective responses (ORR)detailed results A3671009, 2013 1.14 [0.69; 1.88]
CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs I ; all population), 2015 6.11 [3.59; 10.39]
CheckMate 069 (all population), 2015 15.08 [8.07; 28.17]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.82 [0.45; 212.91]
CheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38]
5.32 [2.15 ; 13.16 ] A3671009, 2013, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015 6 89% 2,199 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs I ; all population), 2015 6.35 [4.38; 9.21]
CheckMate 069 (all population), 2015 12.20 [4.41; 33.76]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.80 [0.45; 211.42]
CheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60]
6.30 [3.76 ; 10.57 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015 5 60% 1,544 low not evaluable AE (any grade)detailed results A3671009, 2013 2.22 [1.12; 4.38]
2.22 [1.12 ; 4.38 ] A3671009, 2013 1 0% 644 NA not evaluable AE (grade 3-4)detailed results A3671009, 2013 1.84 [1.35; 2.52]
1.84 [1.35 ; 2.52 ] A3671009, 2013 1 0% 644 NA not evaluable AE leading to death (grade 5)detailed results A3671009, 2013 1.71 [0.85; 3.45]
1.71 [0.85 ; 3.45 ] A3671009, 2013 1 0% 644 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results A3671009, 2013 97.13 [5.95; 1585.40]
97.13 [5.95 ; 1585.40 ] A3671009, 2013 1 0% 644 NA not evaluable SAE (any grade)detailed results A3671009, 2013 3.19 [2.19; 4.65]
3.19 [2.19 ; 4.65 ] A3671009, 2013 1 0% 644 NA not evaluable TRAE (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs I ; all population), 2015 3.70 [1.95; 7.04]
CheckMate 069 (all population), 2015 0.75 [0.19; 2.97]
1.51 [0.55 ; 4.16 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 83% 1,388 low not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs I ; all population), 2015 3.83 [2.74; 5.36]
CheckMate 069 (all population), 2015 3.77 [1.71; 8.31]
2.14 [0.61 ; 7.44 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 96% 1,388 low not evaluable TRAE leading to death (grade 5)detailed results A3671009, 2013 7.00 [0.86; 57.23]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
3.44 [0.64 ; 18.34 ] A3671009, 2013, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015 3 0% 1,892 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [2.72; 5.85]
CheckMate 069 (all population), 2015 4.18 [1.76; 9.91]
CheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19]
2.46 [0.91 ; 6.69 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF wild type), 2015 4 91% 1,496 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs I ; all population), 2015 2.72 [1.82; 4.06]
CheckMate 069 (all population), 2015 4.14 [1.59; 10.74]
1.74 [0.50 ; 6.11 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 93% 1,388 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 069 (all population), 2015 0.24 [0.01; 7.31]
0.34 [0.06 ; 1.80 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results A3671009, 2013 5.93 [0.30; 118.96]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 069 (all population), 2015 0.24 [0.02; 2.68]
1.99 [0.44 ; 8.99 ] A3671009, 2013, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 4 34% 2,032 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.85 [0.26 ; 13.41 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
0.49 [0.10 ; 2.35 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
0.49 [0.01 ; 24.92 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs I ; all population), 2015 1.08 [0.61; 1.93]
CheckMate 069 (all population), 2015 2.94 [0.81; 10.66]
0.73 [0.15 ; 3.51 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 86% 1,388 low not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
0.98 [0.03 ; 29.71 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
2.34 [0.21 ; 26.66 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015 2 0% 1,248 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 4.01 [0.45; 36.11]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.66 [0.31 ; 8.80 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs I ; all population), 2015 1.66 [0.90; 3.06]
CheckMate 069 (all population), 2015 0.98 [0.31; 3.04]
0.95 [0.42 ; 2.14 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 65% 1,388 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.37 [0.62; 3.04]
1.36 [0.62 ; 2.95 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015 2 0% 1,248 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
3.44 [0.57 ; 20.83 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 1.24 [0.23; 6.63]
1.24 [0.23 ; 6.63 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results A3671009, 2013 0.98 [0.02; 49.62]
0.98 [0.02 ; 49.62 ] A3671009, 2013 1 0% 644 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs I ; all population), 2015 4.45 [1.26; 15.77]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
2.66 [0.95 ; 7.46 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 12% 1,388 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 2.22 [0.77; 6.34]
2.22 [0.77 ; 6.34 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 069 (all population), 2015 1.98 [0.09; 44.77]
1.43 [0.27 ; 7.51 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Hepatitis TRAE (grade 3-4)detailed results A3671009, 2013 3.94 [0.18; 87.81]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 10.08 [0.55; 185.32]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
3.86 [0.79 ; 18.86 ] A3671009, 2013, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 4 0% 2,032 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 15.93 [0.93; 273.74]
15.93 [0.93 ; 273.74 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.88 [0.25 ; 14.47 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.28; 3.47]
CheckMate 069 (all population), 2015 0.48 [0.07; 3.51]
0.61 [0.24 ; 1.59 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.06 [0.12 ; 9.11 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs I ; all population), 2015 9.98 [2.31; 43.24]
CheckMate 069 (all population), 2015 7.32 [0.41; 131.94]
4.79 [1.35 ; 17.01 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 25% 1,388 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs I ; all population), 2015 5.78 [2.20; 15.21]
CheckMate 069 (all population), 2015 10.83 [0.62; 189.76]
3.07 [0.64 ; 14.80 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 69% 1,388 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs I ; all population), 2015 3.04 [1.54; 5.98]
CheckMate 069 (all population), 2015 4.19 [0.51; 34.53]
2.11 [0.98 ; 4.53 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 46% 1,388 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
3.55 [0.87 ; 14.52 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.36 [0.17 ; 10.56 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 3.53 [0.73; 17.15]
CheckMate 069 (all population), 2015 0.48 [0.03; 7.91]
1.15 [0.21 ; 6.28 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 35% 1,388 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results A3671009, 2013 5.93 [0.30; 118.96]
5.93 [0.30 ; 118.96 ] A3671009, 2013 1 0% 644 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 3.00 [0.31; 29.00]
CheckMate 069 (all population), 2015 0.98 [0.09; 11.08]
1.53 [0.37 ; 6.33 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
0.78 [0.08 ; 7.57 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
2.48 [0.55 ; 11.24 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
1.63 [0.31 ; 8.42 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 2.02 [0.68; 5.98]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
1.21 [0.23 ; 6.46 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 54% 1,388 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
0.98 [0.03 ; 29.71 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 1.48 [0.15; 14.67]
1.48 [0.15 ; 14.67 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 9.64 [0.55; 170.02]
9.64 [0.55 ; 170.02 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
1.48 [0.11 ; 19.28 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015 2 0% 1,248 low not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.06 [0.12 ; 9.11 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 7.09 [0.87; 57.98]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
2.71 [0.60 ; 12.20 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 3 0% 1,388 low not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.02; 14.84]
0.50 [0.04 ; 5.48 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015 2 0% 1,248 low not evaluable Abdominal pain AE (grade 3-4)detailed results A3671009, 2013 4.04 [1.13; 14.45]
4.04 [1.13 ; 14.45 ] A3671009, 2013 1 0% 644 NA not evaluable Asthenia AE (grade 3-4)detailed results A3671009, 2013 0.10 [0.01; 1.78]
0.10 [0.01 ; 1.78 ] A3671009, 2013 1 0% 644 NA not evaluable Constipation AE (grade 3-4)detailed results A3671009, 2013 0.98 [0.14; 7.01]
0.98 [0.14 ; 7.01 ] A3671009, 2013 1 0% 644 NA not evaluable Cough AE (grade 3-4)detailed results A3671009, 2013 1.97 [0.07; 58.81]
1.97 [0.07 ; 58.81 ] A3671009, 2013 1 0% 644 NA not evaluable Decreased appetite AE (grade 3-4)detailed results A3671009, 2013 14.32 [1.87; 109.52]
14.32 [1.87 ; 109.52 ] A3671009, 2013 1 0% 644 NA not evaluable Dyspnoea AE (grade 3-4)detailed results A3671009, 2013 4.00 [0.84; 18.98]
4.00 [0.84 ; 18.98 ] A3671009, 2013 1 0% 644 NA not evaluable Fatigue AE (grade 3-4)detailed results A3671009, 2013 3.90 [1.44; 10.57]
3.90 [1.44 ; 10.57 ] A3671009, 2013 1 0% 644 NA not evaluable Headache AE (grade 3-4)detailed results A3671009, 2013 1.97 [0.18; 21.82]
1.97 [0.18 ; 21.82 ] A3671009, 2013 1 0% 644 NA not evaluable Nausea AE (grade 3-4)detailed results A3671009, 2013 1.39 [0.61; 3.18]
1.39 [0.61 ; 3.18 ] A3671009, 2013 1 0% 644 NA not evaluable Neutropenia AE (grade 3-4)detailed results A3671009, 2013 0.03 [0.00; 0.19]
0.03 [0.00 ; 0.19 ] A3671009, 2013 1 0% 644 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results A3671009, 2013 4.97 [0.58; 42.77]
4.97 [0.58 ; 42.77 ] A3671009, 2013 1 0% 644 NA not evaluable Pruritus AE (grade 3-4)detailed results A3671009, 2013 5.93 [0.30; 118.96]
5.93 [0.30 ; 118.96 ] A3671009, 2013 1 0% 644 NA not evaluable Pyrexia AE (grade 3-4)detailed results A3671009, 2013 7.94 [0.42; 150.76]
7.94 [0.42 ; 150.76 ] A3671009, 2013 1 0% 644 NA not evaluable Rash AE (grade 3-4)detailed results A3671009, 2013 7.00 [0.86; 57.23]
7.00 [0.86 ; 57.23 ] A3671009, 2013 1 0% 644 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results A3671009, 2013 0.03 [0.00; 0.26]
0.03 [0.00 ; 0.26 ] A3671009, 2013 1 0% 644 NA not evaluable Vomiting AE (grade 3-4)detailed results A3671009, 2013 1.55 [0.66; 3.64]
1.55 [0.66 ; 3.64 ] A3671009, 2013 1 0% 644 NA not evaluable Weight decreased AE (grade 3-4)detailed results A3671009, 2013 0.98 [0.06; 15.76]
0.98 [0.06 ; 15.76 ] A3671009, 2013 1 0% 644 NA not evaluable 0.0 200.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-14 15:48 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 285,68,127,128
- treatments: 504,850,329,558,579,549,868,502,741,556
